MAPT and Alzheimer disease: One strength of this study is that the patient groups were very precisely defined in terms of clinical phenotype and relevant pathophysiological biomarkers, including CSF AD biomarkers, amyloid and tau PET imaging, as well as a 2-year clinical follow-up.